Splicing Deregulation and Splicing Modulation in Acute Myeloid Leukemia: DNA is not Destiny

Inge Margaretha van der Werf

    Research output: PhD ThesisPhD-Thesis - Research and graduation internal

    385 Downloads (Pure)

    Abstract

    Cancer is thought to arise from accumulation of DNA mutations. However, AML is a heterogeneous disease characterized by diverse mutations each occurring at low frequencies. Actually, AML is a subtype with a relatively low mutational load compared to other cancer types. In addition, in children, DNA is far less damaged by exposure or age. Thus, also AML might not only be driven by differences in genomic content but also by transcriptomic heterogeneity. In this thesis we aimed to study deregulated splicing in AML and uncover its role in leukemogenesis.
    Original languageEnglish
    QualificationDr.
    Awarding Institution
    • Vrije Universiteit Amsterdam
    Supervisors/Advisors
    • Kaspers, G.J.L., Supervisor, -
    • Cloos, J., Supervisor, -
    • Wojtuszkiewicz, Anna Monika, Co-supervisor, -
    • Groen, R., Co-supervisor, -
    Award date1 Feb 2022
    Publication statusPublished - 1 Feb 2022

    Keywords

    • Alternative Splicing
    • Splicing Modulation
    • Splicing Deregulation
    • Splicing Factor Mutation
    • SF3B1
    • FLT3/ITD
    • Acute Myeloid Leukemia
    • Pediatric Acute Myeloid Leukemia

    Fingerprint

    Dive into the research topics of 'Splicing Deregulation and Splicing Modulation in Acute Myeloid Leukemia: DNA is not Destiny'. Together they form a unique fingerprint.

    Cite this